Catalyst Pharmaceuticals, Inc.
CPRX
Rank in Stocks
#4165
Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables,... Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables, Florida, operates as a commercial-stage biopharmaceutical enterprise. This company is dedicated to discovering, developing, and marketing therapeutic solutions for individuals in the United States who are afflicted with uncommon, severe, and long-term neuromuscular and neurological disorders. Among its key offerings is Firdapse, an amifampridine phosphate tablet formulation approved for managing Lambert-Eaton Myasthenic Syndrome (LEMS). Catalyst also provides Ruzurgi, a specific treatment option for pediatric patients diagnosed with LEMS. Beyond its existing products, Catalyst is actively investigating additional applications for Firdapse, including its potential use in treating MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and hereditary neuropathy with liability to pressure palsies. The company engages in various strategic collaborations, such as licensing agreements with BioMarin Pharmaceutical Inc., and a joint development and commercialization agreement with Endo Ventures Limited concerning a generic version of Sabril tablets. Previously known as Catalyst Pharmaceutical Partners, Inc., the company adopted its current name in May 2015.
Share Price
$31.49
Last synced: 2026-07-21
Market Cap
$3.85B
Change (1 day)
0.00%
Change (1 year)
49.88%
Country
US
Trade Catalyst Pharmaceuticals, Inc. (CPRX)
Category
Healthcare
Revenue for Catalyst Pharmaceuticals, Inc. (CPRX)
Revenue in Mar 2026 TTM: $596.96M
According to Catalyst Pharmaceuticals, Inc. latest financial reports the company's current revenue (TTM) is $596.96M. In 2023 the company made a revenue of $398.20M an increase over the revenue in the year 2022 that was $214.20M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Catalyst Pharmaceuticals, Inc. from 2002 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| 2026 (TTM) | $596.96M | 21.40% |
| 2024 | $491.73M | 23.49% |
| 2023 | $398.20M | 85.90% |
| 2022 | $214.20M | 52.10% |
| 2021 | $140.83M | 18.27% |
| 2020 | $119.07M | 16.39% |
| 2019 | $102.31M | 20,361.20% |
| 2018 | $500.00K | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
| 2015 | 0.00 | 0.00% |
| 2014 | 0.00 | 0.00% |
| 2013 | 0.00 | 0.00% |
| 2012 | 0.00 | 0.00% |
| 2011 | 0.00 | -100.00% |
| 2010 | $488.96K | 0.00% |
| 2009 | 0.00 | 0.00% |
| 2008 | 0.00 | 0.00% |
| 2007 | 0.00 | 0.00% |
| 2006 | 0.00 | 0.00% |
| 2005 | 0.00 | 0.00% |
| 2004 | 0.00 | 0.00% |
| 2003 | 0.00 | 0.00% |
| 2002 | 0.00 | 0.00% |
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| $12.62B | 2,014.77% |
US
|
|
| $2.23B | 273.23% |
US
|
|
| $15.74B | 2,537.43% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 908.66% |
NL
|
